DDInter1945 DDInter808
Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expressed on platelets, vorapaxar prevents thrombin-related platelet aggregation.
Garlic allergenic extract is used in allergenic testing.
Vorapaxar {u} may cause a minor interaction that can limit clinical effects when taken with {v} Chamomile
Vorapaxar {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hemin
Vorapaxar {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Vorapaxar {u} may lead to a major life threatening interaction when taken with {v} Anagrelide
Vorapaxar {u} may lead to a major life threatening interaction when taken with {v} Troleandomycin
Vorapaxar may cause a minor interaction that can limit clinical effects when taken with Chamomile
Vorapaxar may cause a moderate interaction that could exacerbate diseases when taken with Hemin
Vorapaxar may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Vorapaxar may lead to a major life threatening interaction when taken with Anagrelide
Vorapaxar may lead to a major life threatening interaction when taken with Troleandomycin